Gamma Knife Dosimetric Differences, TMR 10 Versus Convolution Algorithm

Sponsor
University College, London (Other)
Overall Status
Unknown status
CT.gov ID
NCT02374983
Collaborator
University College London Hospitals (Other)
100
1
36
2.8

Study Details

Study Description

Brief Summary

Gamma Knife Radiosurgery (GKR) is a well established treatment modality for brain tumors and functional disorders of the brain. It relies on mathematical algorithms to predict dose distribution and to calculate the dose at arbitrary points in the head. For the last 25 years, doses applied using Gamma Knife Radiosurgery have been calculated using a simple algorithm, called the Tissue Maximum Ratio algorithm (TMR). Dose planning using this algorithm, relies on a number of approximations to enable fast isodose computation during treatment planning. One of the most significant of these is the approximation of the head to water-equivalent density. The increased electron density of brain and bone (relative to water) and the near-zero density of air cavities in the skull may make significant perturbations to isodose and beam-on time calculations.

With the advent of faster workstations, the effect of tissue in-homogeneities can finally be calculated in reasonable time during the treatment planning process; a newer, more modern algorithm known as convolution algorithm is now commercially available. It uses the values of density indicated in the CT scan to predict the dose distribution and is expected to more accurately calculate radiation dose, although it needs further investigation before clinical implementation. Inter- and intra-indication differences between the old and new algorithms need to be understood before this method can be confidently employed in a clinical setting. It is the aim of this study to understand the dosimetric differences between these dose calculation algorithms and to evaluate the implications of using the convolution algorithm for GKR. A large number of treatments will be re-planned using the convolution algorithm and compared to the TMR plans used to treat the patients. Beam-on-time, which is proportional to dose and a number of commonly used metrics for the targets such as coverage, selectivity, gradient index, and mean and maximum dose, will be estimated with both algorithms. Subgroup analysis will be done to assess whether any factor such as diagnosis, size of the head or location of the target could impact on the relative difference between the methods. The treatment plans will be compared and the potential implications on treatment planning will be elucidated.

Condition or Disease Intervention/Treatment Phase
  • Other: Gamma knife radiosurgery re-planning with convolution algorithm

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Time Perspective:
Prospective
Official Title:
Evaluation of Dosimetric Differences Between the TMR 10 and Convolution Algorithm for Gamma Knife Radiosurgery Planning
Study Start Date :
Oct 1, 2013
Anticipated Primary Completion Date :
Oct 1, 2015
Anticipated Study Completion Date :
Oct 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Research group

The group will consist of 100 patients (200 observations) receiving Gamma Knife treatment. Radiosurgery treatments will be re-planned using the convolution algorithm and compared to the TMR plans used to treat the patients.

Other: Gamma knife radiosurgery re-planning with convolution algorithm
The convolution algorithm, which uses the correlation between CT imaging density in Hounsfield units (HU) and electron density (ρe) of the tissues as input to predict dose distribution, can provide a better simulation of real delivered dose for GKR. By more accurately predicting the dose delivered, a better prediction of clinical effects can be made, increasing the potential clinical efficacy of treatment. Convolution algorithm is now available in Leksell GammaPlan® 10 but there is not enough clinical data to support its use over TMR 10, which is the current clinical standard. Using convolution algorithm to recalculate the dose for the otherwise unaltered TMR 10 plan will provide valuable insight and understanding of the dosimetric differences between these planning algorithms.

Outcome Measures

Primary Outcome Measures

  1. Beam-on time (difference in the Beam-on-time of the treatment plans obtained using TMR 10 and convolution algorithm for each lesion treated) [Beam-on time obtained with the TMR 10 algorithm at the time of treatment (baseline) vs Beam-on time observed when the treatment is re-planned with the convolution algorithm, that being a few hours after the actual treatment is delivered (maximum 1 day)]

    The difference in the Beam-on-time of the treatment plans obtained using TMR 10 and convolution algorithm for each lesion treated will be the primary outcome of the study

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult patients receiving Gamma Knife treatment for any diagnosis in the Gamma Knife centre at QSRC.

  • The subject consents to participate in the study and consent to have a stereotactic non contrast CT scan of the brain after GKR has finished.

Exclusion Criteria:
  • Inability to consent

  • Younger than 18 years of age: Children are not eligible to give consent by themselves and at the moment only adults are being treated at the QSRC.

  • Patient is not suitable for CT scan: There are no absolute clinical contraindications for CT scan. However, for the purpose of the study, pregnancy is considered an absolute contraindication. Claustrophobia or anxiety disorders are considered a relative contraindication; however, this is more likely to affect the subject ability to tolerate Gamma Knife treatment and MRI scanning, which would make the patient not eligible or the study.

  • Co-morbidity or previous treatment in the patient is not to be considered as exclusion criteria.

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Gamma Knife Centre at Queen Square London London,City of United Kingdom WC1N 3BG

Sponsors and Collaborators

  • University College, London
  • University College London Hospitals

Investigators

  • Study Chair: Neil Kitchen, The National Hospital for Neurology and Neurosurgery

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University College, London
ClinicalTrials.gov Identifier:
NCT02374983
Other Study ID Numbers:
  • 13/0188
  • 13/LO/085
  • 128269
First Posted:
Mar 2, 2015
Last Update Posted:
Mar 2, 2015
Last Verified:
Feb 1, 2015
Keywords provided by University College, London

Study Results

No Results Posted as of Mar 2, 2015